CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade ARCA Biopharma - ABIO CFD

Market is not available at the moment

Market information is presented
as of 2023-09-21

  • Summary
Trading Conditions
Spread -
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026151 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026151%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003929 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003929%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* N/A
Open* N/A
1-Year Change* N/A
Day's Range* N/A
52 wk Range 1.85-2.70
Average Volume (10 days) 22.87K
Average Volume (3 months) 477.94K
Market Cap 29.40M
P/E Ratio -100.00K
Shares Outstanding 14.41M
Revenue N/A
EPS -0.44
Dividend (Yield %) N/A
Beta 1.28
Next Earnings Date Oct 26, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

Date Close Change Change (%) Open High Low

ARCA Biopharma Events

Time (UTC) Country Event
Thursday, October 26, 2023

Time (UTC)

10:59

Country

US

Event

Q3 2023 ARCA Biopharma Inc Earnings Release
Q3 2023 ARCA Biopharma Inc Earnings Release

Forecast

-

Previous

-
Thursday, February 22, 2024

Time (UTC)

10:59

Country

US

Event

Q4 2023 ARCA Biopharma Inc Earnings Release
Q4 2023 ARCA Biopharma Inc Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 10.596 19.335 9.766 5.814 8.118
Selling/General/Admin. Expenses, Total 5.847 5.503 4.774 3.981 3.879
Research & Development 4.749 13.832 4.992 1.833 4.239
Operating Income -10.596 -19.335 -9.766 -5.814 -8.118
Interest Income (Expense), Net Non-Operating 0.675 0.013 0.019 0.165 0.154
Net Income Before Taxes -9.926 -19.322 -9.747 -5.649 -7.964
Net Income After Taxes -9.926 -19.322 -9.738 -5.482 -7.933
Net Income Before Extra. Items -9.926 -19.322 -9.738 -5.482 -7.933
Net Income -9.926 -19.322 -9.738 -5.482 -7.933
Income Available to Common Excl. Extra. Items -9.926 -19.322 -9.738 -5.482 -7.933
Income Available to Common Incl. Extra. Items -9.926 -19.322 -9.738 -5.482 -7.933
Diluted Net Income -9.926 -19.322 -9.738 -5.482 -7.933
Diluted Weighted Average Shares 14.4101 13.9039 4.71024 1.32123 0.76939
Diluted EPS Excluding Extraordinary Items -0.68882 -1.38968 -2.06741 -4.14915 -10.3107
Diluted Normalized EPS -0.68882 -1.38968 -2.06741 -4.14915 -10.3107
Other, Net -0.005
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 1.973 1.796 1.548 2.552 3.219
Selling/General/Admin. Expenses, Total 1.719 1.406 1.487 1.528 1.734
Research & Development 0.254 0.39 0.061 1.024 1.485
Operating Income -1.973 -1.796 -1.548 -2.552 -3.219
Interest Income (Expense), Net Non-Operating 0.493 0.45 0.374 0.222 0.072
Net Income Before Taxes -1.48 -1.346 -1.174 -2.333 -3.147
Net Income After Taxes -1.48 -1.346 -1.174 -2.333 -3.147
Net Income Before Extra. Items -1.48 -1.346 -1.174 -2.333 -3.147
Net Income -1.48 -1.346 -1.174 -2.333 -3.147
Income Available to Common Excl. Extra. Items -1.48 -1.346 -1.174 -2.333 -3.147
Income Available to Common Incl. Extra. Items -1.48 -1.346 -1.174 -2.333 -3.147
Diluted Net Income -1.48 -1.346 -1.174 -2.333 -3.147
Diluted Weighted Average Shares 14.4101 14.4101 14.4101 14.4101 14.4101
Diluted EPS Excluding Extraordinary Items -0.10271 -0.09341 -0.08147 -0.1619 -0.21839
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.10271 -0.09341 -0.08147 -0.1619 -0.21839
Other, Net 0 0 0 -0.003 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 42.699 54.421 49.968 8.48 6.777
Cash and Short Term Investments 42.445 53.359 49.071 8.363 6.608
Cash & Equivalents 42.445 53.359 49.071 8.363 6.608
Short Term Investments 0
Other Current Assets, Total 0.254 1.062 0.897 0.117 0.169
Total Assets 43.085 54.924 50.429 8.536 6.825
Property/Plant/Equipment, Total - Net 0.368 0.485 0.449 0.032 0.024
Property/Plant/Equipment, Total - Gross 0.572 0.68 0.699 0.399 0.398
Accumulated Depreciation, Total -0.204 -0.195 -0.25 -0.367 -0.374
Long Term Investments
Other Long Term Assets, Total 0.018 0.018 0.012 0.024 0.024
Total Current Liabilities 1.132 3.498 3.499 0.926 0.793
Accounts Payable 0.334 1.117 1.773 0.418 0.23
Accrued Expenses 0.798 2.381 1.726 0.508 0.563
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 1.412 3.881 3.908 0.926 0.793
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.28 0.383 0.409 0
Total Equity 41.673 51.043 46.521 7.61 6.032
Common Stock 0.014 0.014 0.01 0.002 0.014
Additional Paid-In Capital 225.061 224.505 200.665 152.024 144.952
Retained Earnings (Accumulated Deficit) -183.402 -173.476 -154.154 -144.416 -138.934
Other Equity, Total
Total Liabilities & Shareholders’ Equity 43.085 54.924 50.429 8.536 6.825
Total Common Shares Outstanding 14.4101 14.4101 9.54815 1.59407 0.77356
Preferred Stock - Non Redeemable, Net 0 0
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Total Current Assets 41.702 42.699 44.55 47.655 50.539
Cash and Short Term Investments 40.85 42.445 43.939 46.437 49.059
Cash & Equivalents 40.85 42.445 43.939 46.437 49.059
Other Current Assets, Total 0.852 0.254 0.611 1.218 1.48
Total Assets 42.059 43.085 44.965 48.101 51.014
Property/Plant/Equipment, Total - Net 0.339 0.368 0.397 0.428 0.457
Property/Plant/Equipment, Total - Gross 0.547 0.572 0.598 0.632 0.655
Accumulated Depreciation, Total -0.208 -0.204 -0.201 -0.204 -0.198
Other Long Term Assets, Total 0.018 0.018 0.018 0.018 0.018
Total Current Liabilities 1.266 1.132 1.937 2.809 2.719
Accounts Payable 0.366 0.334 0.593 1.11 1.014
Accrued Expenses 0.9 0.798 1.344 1.699 1.705
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 1.528 1.412 2.238 3.138 3.076
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.262 0.28 0.301 0.329 0.357
Total Equity 40.531 41.673 42.727 44.963 47.938
Common Stock 0.014 0.014 0.014 0.014 0.014
Additional Paid-In Capital 225.265 225.061 224.941 224.844 224.672
Retained Earnings (Accumulated Deficit) -184.748 -183.402 -182.228 -179.895 -176.748
Total Liabilities & Shareholders’ Equity 42.059 43.085 44.965 48.101 51.014
Total Common Shares Outstanding 14.4101 14.4101 14.4101 14.4101 14.4101
Preferred Stock - Non Redeemable, Net 0
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -9.926 -19.322 -9.738 -5.482 -7.933
Cash From Operating Activities -10.912 -18.762 -7.725 -4.801 -8.244
Cash From Operating Activities 0.02 0.016 0.008 0.018 0.022
Non-Cash Items 0.655 0.572 0.128 0.222 0.275
Cash Interest Paid 0 0 0.009 0.007 0.008
Changes in Working Capital -1.661 -0.028 1.877 0.441 -0.608
Cash From Investing Activities -0.002 -0.043 -0.019 -0.004 3.046
Capital Expenditures -0.002 -0.043 -0.019 -0.004 -0.004
Other Investing Cash Flow Items, Total 0 3.05
Cash From Financing Activities 0 23.093 48.452 6.56 3.104
Financing Cash Flow Items 0 -0.977 -2.034 -0.372 -0.117
Issuance (Retirement) of Stock, Net 0 24.07 50.894 7.281 3.532
Issuance (Retirement) of Debt, Net 0 -0.408 -0.349 -0.311
Net Change in Cash -10.914 4.288 40.708 1.755 -2.094
Cash Taxes Paid 0 0 0.009 -0.167
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -1.346 -9.926 -8.752 -6.419 -3.272
Cash From Operating Activities -1.595 -10.912 -9.418 -6.92 -4.298
Cash From Operating Activities 0.004 0.02 0.015 0.011 0.005
Non-Cash Items 0.229 0.655 0.511 0.387 0.192
Cash Taxes Paid 0 0 0 0 0
Cash Interest Paid 0 0 0 0 0
Changes in Working Capital -0.482 -1.661 -1.192 -0.899 -1.223
Cash From Investing Activities 0 -0.002 -0.002 -0.002 -0.002
Capital Expenditures 0 -0.002 -0.002 -0.002 -0.002
Cash From Financing Activities 0 0 0 0 0
Financing Cash Flow Items 0 0 0 0 0
Issuance (Retirement) of Stock, Net 0 0 0 0
Net Change in Cash -1.595 -10.914 -9.42 -6.922 -4.3
Issuance (Retirement) of Debt, Net

ARCA Biopharma Company profile

About Arca Biopharma Inc

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is focused on development and commercialization of targeted therapies for cardiovascular diseases. The Company's lead product includes Recombinant Nematode Anticoagulant Protein c2, or rNAPc2 (AB201) and Gencaro(bucindolol hydrochloride). rNAPc2 (AB201) is a treatment for diseases caused by ribonucleic acid (RNA), viruses, focusing on COVID-19, the disease syndrome caused by the SARS-CoV-2 virus. Gencaro(bucindolol hydrochloride) is a pharmacogenetically-targeted beta-adrenergic receptor antagonist with mild vasodilator properties for the treatment of atrial fibrillation (AF) in patients with heart failure. AF is the form of cardiac arrhythmia, a disruption of the heart’s normal rhythm or rate. The Company is conducting Phase II b clinical trial of rNAPc2 (AB201), ASPEN-COVID-19. It is also conducting Phase IIB/III clinical trial of Gencaro.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Arca Biopharma Inc revenues was not reported. Net loss increased 98% to $19.3M. Higher net loss reflects Other -Research and development increase from $5M to $13.7M (expense), other expenses1 increase of 8% to $5.1M (expense), Stock-based Compensation in SGA increase from $17K to $337K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$2.07 to -$1.39.

Equity composition

Common Stock $.001 Par, Insiders own 3.59% . IPO 8/97, 3M shares @$14 by LehmanBrothers, Inc. PO 3/04, 5M shares @ $13 by UBS SecuritiesLLC. 2/03, Company merged with Variagenics, Inc. andchanged name from Hyseq, Inc. 01/09, Name changed fromNuvelo, Inc. 03/13, 1-for-6 reverse stock split. 9/15, 1-for-7 reverse stock split.

Industry: Bio Therapeutic Drugs

Suite 430
8001 Arista Place
BROOMFIELD
COLORADO 80021
US

News

EUR/USD tests key support

EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

14:32, 21 September 2023
Bank of England building

BoE leaves rates unchanged, GBP drops further as investors look for more clarity

The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

11:45, 21 September 2023
British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

GBP softer after CPI surprise, JPY focused on any further hints from Ueda

GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

12:42, 20 September 2023

How to Trade The Break & Retest

In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

11:59, 20 September 2023

Cable coils near lows ahead of Fed and BoE rate decisions

It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

14:16, 19 September 2023

FTSE 100 Technical Outlook - 18 September 2023

In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

06:55, 19 September 2023
View of the City of London’s illuminated financial district skyline at dusk

Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

13:46, 15 September 2023

People also watch

US100

14,710.90 Price
+0.190% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0039%
Overnight fee time 21:00 (UTC)
Spread 7.0

XRP/USD

0.52 Price
+0.830% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01192

BTC/USD

26,596.85 Price
-0.160% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 85.00

ETH/USD

1,595.06 Price
+0.310% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 5.40

Still looking for a broker you can trust?

Join the 555.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading